Skip to content

Study · Not a test of the peptide alone · 2025

1 result

Multidisciplinary Approach to a Transverse Periprosthetic Femur Fracture in a Short-Statured Patient: A Case Report.

Bhatti P, Ortiz S, Ortiz S, Neitzke CC, Lane JM, Gausden EB

JBJS case connector1 Jan 2025Cited by 1 (Europe PMC)

PMID40053675 (opens in a new tab)DOI10.2106/jbjs.cc.24.00523 (opens in a new tab)PepBankPUB-40053675
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneCase report or seriesEfficacy outcome

    In a woman with VACTERL, fracture union occurred after fixation, abaloparatide, and autologous bone grafting with iliac crest aspirate.

    In plain wordsIn one woman, the fracture healed after fixation, abaloparatide, and bone grafting with iliac crest aspirate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableRadiographic fracture union
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The fracture achieved radiographic union 2 years post-ORIF.
    1 context sentence
    Summary · context
    A 43-year-old woman with VACTERL sustained a Vancouver B1 periprosthetic femur fracture (PFF) following right revision total hip arthroplasty with a cemented femoral component. She underwent open reduction and internal fixation (ORIF) with dual plate fixation, and later received abaloparatide and au…

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.